LION: Lifting Immune CheckpOints with NSAIDs
Research type
Research Study
Full title
Pan Tumour Trial of Cox-Inhibitor and Immune Checkpoint Blockade
IRAS ID
1004222
Contact name
Anne Armstrong
Contact email
Sponsor organisation
The Christie NHS Foundation Trust
Eudract number
2021-005109-29
ISRCTN Number
ISRCTN73037722
Research summary
Phase II, open label, multicentre trial of the addition of celecoxib to standard of care immune-checkpoint blockade in Triple Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC)(clear cell and papillary histological subtypes).
This study will compare a potential new treatment combination for patients who TNBC, NSCLC and RCC. The study will check how safe, tolerable and celecoxib is in combination with standard immunotherapy +/- chemotherapy which are the first-line treatments for these patients. It is hoped the new treatments will more effective, but it’s not known at present which is why the study is being performed.The trial will include 89 subjects, across the three disease groups, treated at sites with oncology expertise. To participate, patients must be >18 years and have triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) or renal cell carcinoma (RCC).
Patients will receive the following treatments dependent on their disease type:
1. TNBC; celecoxib, atezolizumab + nab-paclitaxel
2. NSCLC; celecoxib + pembrolizumab
3. RCC; celecoxib, nivolumab + ipilimumabREC name
London - Fulham Research Ethics Committee
REC reference
22/LO/0219
Date of REC Opinion
24 May 2022
REC opinion
Further Information Favourable Opinion